PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells

Oncotarget

Volumn 7, Issue 51, 2016, Pages 84999-85020

  Phadngam, Suratchanee ^a   Castiglioni, Andrea ^a   Ferraresi, Alessandra ^a   Morani, Federica ^a   Follo, Carlo ^a   Isidoro, Ciro ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

AKT; Cancer; Glucose; PTEN; Warburg effect

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 1; GROWTH FACTOR; ISOENZYME; MUTANT PROTEIN; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE B; CELL EXTRACT; ONCOPROTEIN; PROTEIN BINDING; PTEN PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CELL FREE SYSTEM; CELL MEMBRANE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE SILENCING; GLUCOSE INTAKE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; OVARIAN CANCER CELL LINE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSGENICS; WILD TYPE; GENETICS; METABOLISM; OVARY TUMOR; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL EXTRACTS; CELL LINE, TUMOR; CELL MEMBRANE; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN BINDING; PTEN PHOSPHOHYDROLASE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 85007417963     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13113     Document Type: Article

References (58)

1. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11:85-95.
2. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011; 11:325-337.
3. Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism 2016; 65:124-139.
4. Joost HG, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 2002; 282:974-976.
5. Szablewski L. Expression of glucose transporters in cancers. Biochimica et Biophysica Acta 2013; 1835:164-169.
6. Reinicke K, Sotomayor P, Cisterna P, Delgado C, Nualart F, Godoy A. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue. J Cell Biochem 2012; 113:553-562.
7. Matsuzu K, Segade F, Matsuzu U, Carter A, Bowden DW, Perrier ND. Differential expression of glucose transporters in normal and pathological thyroid tissue. Thyroid 2004; 14:806-812.
8. Morani F, Pagano L, Prodam F, Aimaretti G, Isidoro C. Loss of expression of the oncosuppressor PTEN in thyrois incidentalomas associates with GLUT1 plasmamembrane expression. Panminerva Med 2012; 54:59-63.
9. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastasis. Clin Cancer Res 1996; 2:1151-1154.
10. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, Slater G, Weiss A, Burstein DE. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 1998; 83:34-40.
11. Koch A, Lang SA, Wild PJ, Gantner S, Mahli A, Spanier G, Berneburg M, Müller M, Bosserhoff AK, Hellerbrand C. Glucose transporter isoform 1 espression enhance metastasis of malignant melanoma cells. Oncotarget 2015; 6:32748-32760. doi: 10.18632/oncotarget.4977.
12. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, Stoeltzing O, Warnecke C, Schölmerich J, Oefner PJ, Kreutz M, Bosserhoff AK, Hellerbrand C. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009; 174:1544-1552.
13. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer 1993; 72:2979-2985.
14. Ravazoula P, Batistatou A, Aletra C, Ladopoulos J, Kourounis G, Tzigounis B. Immunoisotchemical expression of glucose transporter Glut1 and cyclin D1 in breast carcinomas with negative lymph nodes. Eur J Gynaecol Oncol 2003; 24:544-546.
15. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, Penalver M, Mancuso S, Scambia G. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001; 92:1144-1150.
16. Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, Qazi A, Hussein Y, Morris RT, Ali-Fehmi R. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol Oncol 2011; 121:181-186.
17. Bilan PJ, Ramlal T, Klip A. IGF-1 mediated recruitment of glucose transporters form intracellular membranes to plasma membrane in L6 muscle cells. Adv Exp Med Biol 1991; 293:273-288.
18. Cheng JC, McBrayer SK, Coarfa C, Dalva-Aydemir S, Gunaratne PH, Carpten JD, Keats JK, Rosen ST, Shanmugam M. Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma. Cancer Metab 2013; 1:14.
19. Yuasa T, Uchiyama K, Ogura Y, Kimura M, Teshigawara K, Hosaka T, Tanaka Y, Obata T, Sano H, Kishi K, Ebina Y. The Rab GTPase-activating protein AS160 as a common regulator of insulin-and Galphaq-mediated intracellular GLUT4 vesicle distribution. Endocr J 2009; 56:345-359.
20. Morani F, Phadngam S, Follo C, Titone R, Aimaretti G, Galetto A, Alabiso O, Isidoro C. PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. J Mol Endocrinol 2014; 53:247-258.
21. Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, Anastasiou D, Ito K, Sasaki AT, Rameh L, Carracedo A, Vander Heiden MG, Cantley LC et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 2012; 149:49-62.
22. Morani F, Phadngam S, Follo C, Titone R, Thongrakard V, Galetto A, Alabiso O, Isidoro C. PTEN deficiency and mutant p53 confer glucose-addiction to thyroid cancer cells: impact of glucose depletion on cell proliferation, cell survival, autophagy and cell migration. Genes Cancer 2014; 5:226-239. doi: 10.18632/genesandcancer.21.
23. Zhang L, Shi L, Zhao X, Wang Y, Yue W. PIK3CA gene mutation associated with poor prognosis of lung adenocarcinomas. Onco Targets Ther 2013; 6:497-502.
24. Oda K, Okada J, Timmerman L, Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res 2008; 68:8127-8136.
25. Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG. An activating PI3kCA mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 2012; 122:553-557.
26. O'Neil RG, Wu L, Mullani N. Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells. Mol Imaging Biol 2005; 7:388-392.
27. Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Sci 2008; 99:1218-1226.
28. Gravina GL, Biordi L, Martella F, Flati V, Ricevuto E, Ficorella C, Tombolini V, Festuccia C. Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int J Oncol 2009; 35:1133-1139.
29. Khan MA, Hussain A, Sundaram MK, Alalami U, Gunasekera D, Ramesh L, Hamza A, Quraishi U. Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Oncol Rep 2015; 33:1976-1984.
30. Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K, Yokota J, Tanaka T. Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 2000; 85:160-165.
31. Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Kato S, Han SY, Suzuki T, Shibata H, Kanamaru R, Ishioka C. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin Cancer Res 2000; 6:3937-3943.
32. Maier D, Jones G, Li X, Schönthal AH, Gratzl O, Van Meier EG, Merlo A. The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 1999; 59:5479-5482.
33. Han SY, Kato H, Kato S, Suzuki T, Shibata H, Ishii S, Shiiba K, Matsuno S, Kanamaru R, Ishioka C. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay. Cancer Res 2000; 60:3147-3151.
34. Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF, Theodorescu D. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene 2004; 40:6788-6797.
35. Wu H1, Wang S, Weng D, Xing H, Song X, Zhu T, Xia X, Weng Y, Xu G, Meng L, Zhou J, Ma D. Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene. Cancer Lett 2008; 2:205-214.
36. Yecies JL, Manning BD. mTOR links oncogenic signalling to tumor cell metabolism. Journal of Molecular Medicine 2011; 89:221-228.
37. Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med 2012; 209:211-215.
38. Shibuya K, Okada M, Suzuki S, Seino M, Seino S, Takeda H, Kitanak C. Targeting the facilitative glucose transporter GLUT1 inhibits the self-renewal and tumor-initiating capacity of cancer stem cells. Oncotarget 2015; 6:651-661. doi: 10.18632/oncotarget.2892.
39. Seo S, Hatano E, Higashi T, Nakajima A, Nakamoto Y, Tada M, Tamaki N, Iwaisako K, Kitamura K, Ikai I, Uemoto S. P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro. Int J Oncol 2009; 34:1303-1312.
40. Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism 2016; 65:124-139.
41. Tian W, Wang Y, Xu Y, Guo X, Wang B, Sun L, Liu L, Cui F, Zhuang Q, Bao X, Schley G, Chung TL, Laslett AL et al. The hypoxia-inducible factor renders cancer cells more sensitive to vitamin C-induced toxicity. J Biol Chem 2014; 289:3339-3351.
42. Hevia D, Gonzalez-Menedez P, Quiros-Gonzalez, Miar A, Rodríguez-García A, Tan DX, Reiter RJ, Mayo JC, Sainz RM. Melatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer. J Pineal Res 2015; 58:234-250.
43. Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P, Zheng X, Sadee W, Sun D. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 2007; 59:495-505.
44. Dwarakanath B, Jain V. Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Future Oncol 2009; 5:581-585.
45. Elf SE, Chen J. Targeting glucose metabolism in patients with cancer. Cancer 2014; 120:774-780.
46. Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, Ciuffreda L. PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol 2015; 16:5-24.
47. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 14:2954-2963.
48. Yin Y, Shen WH. PTEN: a new guardian of the genome. Oncogene 2008; 41:5443-5453.
49. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 1:64-67.
50. Bermúdez Brito M, Goulielmaki E, Papakonstanti EA. Focus on PTEN Regulation. Front Oncol 2015; 5:166.
51. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual specificity phosphatase. Proc Natl Acad Sci USA 1997; 94:9052-9057.
52. Park MJ, Kim MS, Park IC, Kang HS, Yoo H, Park SH, Rhee CH, Hong SI, Lee SH. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res 2002; 21:6318-6322.
53. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, Sahin AA, Esteva FJ, Hortobagyi GN, Yu D. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 4:461-469.
54. Gu T, Zhang Z, Wang J, Guo J, Shen WH, Yin Y. CREB is a novel nuclear target of PTEN phosphatase. CancerRes 2011; 71:2821-2825.
55. Shi Y, Wang J, Chandarlapaty S, Cross J, Thompson C, Rosen N, Jiang X. PTEN is a protein tyrosine phosphatase for IRS1. Nat Struct Mol Biol 2014; 21:522-527.
56. Kuo YC, Huang KY, Yang CH, Yang YS, Lee WY, Chiang CW. Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem. 2008 Jan 25; 283:1882-92.
57. Follo C, Isidoro C. A fast and simple method for simultaneously mixed site-specific mutagenesis of a wide coding sequence. Biotechnol Appl Biochem 2008; 49:175-183.
58. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y, Dixon JE, Pandolfi P, Pavletich NP. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999; 99:323-334